L-2'-methyltyrosine | 70680-92-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-2'-methyltyrosine
• 英文别名: (2S)-2-azaniumyl-3-(4-hydroxy-2-methylphenyl)propanoate
• CAS: 70680-92-1
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: AXEOMQHKTSGLGS-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  L-2'-methyltyrosine 以 重水 为溶剂， 反应 24.0h， 以43%的产率得到α-D-L-2-methyltyrosine
  参考文献：
  名称：

  利用含有色氨酸酶的大肠杆菌B / It7-A细胞制备α-氘化的L-氨基酸

  摘要：

  报道了一种通过富含色氨酸酶的冻干B / It7-A细胞催化的D 2 O中立体定向同位素交换制备α-氘代L-氨基酸的简便方法

  DOI：

  10.1016/s0040-4039(00)97240-x
• 作为产物：
  描述：

  7-羟基-1,2,3,4-四氢异喹啉-3-羧酸 在 palladium on activated charcoal 氢气 作用下， 以 溶剂黄146 为溶剂， 60.0 ℃ 、506.62 kPa 条件下， 反应 24.0h， 生成 L-2'-methyltyrosine 、 D-2'-methyltyrosine
  参考文献：
  名称：

  Synthesis and in vitro opioid activity profiles of DALDA analogues

  摘要：

  The tetrapeptide DALDA (H-Tyr-D-Arg-Phe-Lys-NH2) is a polar and selective mu agonist showing poor penetration of the placental and blood-brain barriers. In an effort to enhance the potency of DALDA, analogues containing 2',6'-dimethyltyrosine (Dmt), N,2',6'-trimethyltyrosine (Tmt), 2'-methyltyrosine (Mmt) or 2'-hydroxy,6'-methyltyrosine (Hmt) in place of Tyr(1), or Om or alpha,gamma -diaminobutyric acid (A(2)bu) in place of Lys(4), were synthesized. All compounds displayed high mu receptor selectivity in the rat and guinea pig brain membrane binding assays and most of them were more potent mu agonists than DALDA in the mu receptor-representative guinea pig ileum assay, with [Dmt(1)]DALDA showing the highest potency. Because of its extraordinary mu agonist potency, high mu selectivity, polar character (charge of 3+) and metabolic stability, [Dmt(1)]DALDA has potential for use in obstetrical or peripheral analgesia. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)01171-5

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：M3 BIOTECHNOLOGY INC

  公开号：WO2017210489A1

  公开（公告）日：2017-12-07

  The present technology relates to compounds, kits, compositions, and methods useful for the treatment of numerous pathologies including dementia, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases, spinal cord injury, traumatic brain injury, diabetes and metabolic syndrome, defective wound healing, and/or sensorineural hearing and vision loss.

  当前技术涉及化合物、试剂盒、组合物以及用于治疗多种病理状况的方法，包括痴呆症、阿尔茨海默病、帕金森病、肌萎缩侧索硬化症以及其他神经退行性疾病，脊髓损伤、创伤性脑损伤、糖尿病和代谢综合征、伤口愈合缺陷以及/或感音神经性听力和视力损失。
• AROMATIC-CATIONIC PEPTIDES AND USES OF SAME
  申请人：Szeto Hazel H.

  公开号：US20120329730A1

  公开（公告）日：2012-12-27

  The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

  该披露提供了芳香性阳离子肽组合物以及使用这些组合物预防或治疗疾病的方法。该方法包括向需要的对象施用有效量的芳香性阳离子肽。
• [EN] AROMATIC-CATIONIC PEPTIDES CONJUGATED TO ANTIOXIDANTS AND THEIR USE IN TREATING COMPLEX REGIONAL PAIN SYNDROME<br/>[FR] PEPTIDES AROMATIQUES-CATIONIQUES CONJUGUÉS À DES ANTIOXYDANTS ET LEUR UTILISATION DANS LE TRAITEMENT D'UN SYNDROME DOULOUREUX RÉGIONAL COMPLEXE
  申请人：SCHILLER PETER

  公开号：WO2017093897A1

  公开（公告）日：2017-06-08

  Compositions comprising an antioxidant directed or indirectly conjugated to an aromatic-cationic peptide are provide. Said antioxidants are selected from TEMPO, Tro, PBN, AHDP, DBHP, Caf and Hem and may be conjugated to the aromatic-cationic peptide directly or indirectly via a linker to the N-terminus, C-terminus or a side chain of an amino acid residue of the aromatic-cationic peptide. In some embodiments, the aromatic-cationic peptide is 2',6'-Dmt-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2 or D-Arg-2',6'-Dmt-Lys-Phe-NH2. These conjugates have increased antioxidant activity as compared to the unconjugated aromatic-cationic peptide and have utility in treating complex regional pain syndrome.

  提供了包含直接或间接与芳香-阳离子肽结合的抗氧化剂的组合物。所述抗氧化剂从TEMPO、Tro、PBN、AHDP、DBHP、Caf和Hem中选择，并且可以通过连接剂直接或间接地与芳香-阳离子肽结合到N-末端、C-末端或芳香-阳离子肽的氨基酸残基的侧链。在某些实施例中，芳香-阳离子肽为2',6'-Dmt-D-Arg-Phe-Lys-NH2、Phe-D-Arg-Phe-Lys-NH2或D-Arg-2',6'-Dmt-Lys-Phe-NH2。与未结合的芳香-阳离子肽相比，这些共轭物具有增强的抗氧化活性，并可用于治疗复杂性区域性疼痛综合征。
• Pharmaceutically active fluoromethyltyrosine compounds
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0451422A1

  公开（公告）日：1991-10-16

  This invention relates to novel monofluoromethyl- and difluoromethyltyrosine compounds which are active as tyrosine hydroxylase inhibitors and are therefore useful in the treatment of conditions caused by high levels of catecholamines such as hypertension, schizophrenia, and pheochromocytoma.

  这项发明涉及新颖的单氟甲基和二氟甲基酪氨酸化合物，这些化合物作为酪氨酸羟化酶抑制剂具有活性，因此在治疗由高儿茶酚胺水平引起的疾病，如高血压、精神分裂症和嗜铬细胞瘤方面具有用途。
• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。